Amphibian antimicrobial peptides and Protozoa: Lessons from parasites

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 8, 2009, Pages 1570-1581

  Rivas, Luis ^a   Luque Ortega, Juan Román ^a   Andreu, David ^b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Antiprotozoal peptide; Cryptosporidium; Leishmania; Parasite glycocalix; Plasma membrane; Plasmodium

Indexed keywords

AZITHROMYCIN; BOMBININ; BUFORIN; DERMASEPTIN; GRAMICIDIN S; KETOCONAZOLE; LASALOCID; MAGAININ 2; MAGAININ B; MAGAININ H; MINOCYCLINE; MSI 103; MSI 94; NEOMYCIN; PEXIGANAN; PHYLLOSEPTIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROPAMIDINE ISETHIONATE; RANALEXIN; SILVER NITRATE; TEMPORIN; UNCLASSIFIED DRUG; XENOPSIN;

ACANTHAMOEBA CASTELLANII; ACYLATION; AMPHIBIA; ANTIPROTOZOAL ACTIVITY; BACTERIAL VIRULENCE; CELL MEMBRANE; CRYPTOSPORIDIUM PARVUM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SPECIFICITY; EUKARYOTE; FUNGAL VIRULENCE; GLYCOCALYX; HOST CELL; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; MEMBRANE PERMEABILITY; NONHUMAN; PARAMECIUM CAUDATUM; PARASITE VIRULENCE; PATHOGENICITY; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTOZOON; REVIEW; STRUCTURE ACTIVITY RELATION; TETRAHYMENA PYRIFORMIS; TRYPANOSOMA CRUZI;

AMINO ACID SEQUENCE; AMPHIBIAN PROTEINS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIPROTOZOAL AGENTS; GLYCOCALYX; MOLECULAR SEQUENCE DATA; PHOSPHOLIPIDS; PROTOZOA; STRUCTURE-ACTIVITY RELATIONSHIP;

AMPHIBIA; BACTERIA (MICROORGANISMS); CRYPTOSPORIDIUM; EUKARYOTA; PLASMODIUM (APICOMPLEXA); PROTOZOA;

EID: 67649268280     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2008.11.002     Document Type: Review

References (152)

1. Giuliani A., Pirri G., Bozzi A., Di Giulio A., Aschi M., and Rinaldi A.C. Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell. Mol. Life Sci. 65 (2008) 2450-2460
2. Zelezetsky I., and Tossi A. α-Helical antimicrobial peptides-using a sequence template to guide structure-activity relationship studies. Biochim. Biophys. Acta 1758 (2006) 1436-1449
3. Jenssen H., Hamill P., and Hancock R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19 (2006) 491-511
4. Croft S.L. Public-private partnership: from there to here. Trans. R. Soc. Trop. Med. Hyg. 99 Suppl. 1 (2005) S9-S14
5. Molyneux D.H. Control of human parasitic diseases: context and overview. Adv. Parasitol. 61 (2006) 1-45
6. Alvar J., Aparicio P., Aseffa A., Den Boer M., Cañavate C., Dedet J.P., Gradoni L., Ter Horst R., López-Vélez R., and Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21 (2008) 334-359
7. Chan D.I., Prenner E.J., and Vogel H.J. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 1758 (2006) 1184-1202
8. Otvos Jr. L. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci. 11 (2005) 697-706
9. Feder R., Dagan A., and Mor A. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J. Biol. Chem. 275 (2000) 4230-4238
10. Vial H.J., Eldin P., Tielens A.G., and van Hellemond J.J. Phospholipids in parasitic protozoa. Mol. Biochem. Parasitol. 126 (2003) 143-154
11. Papo N., and Shai Y. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes?. Peptides 24 (2003) 1693-1703
12. Huang H.W., Chen F.Y., and Lee M.T. Molecular mechanism of peptide-induced pores in membranes. Phys. Rev. Lett. 92 (2004) 198304
13. Steiner H., Andreu D., and Merrifield R.B. Binding and action of cecropin and cecropin analogues: antibacterial peptides from insects. Biochim. Biophys. Acta 939 (1988) 260-266
14. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 66 (2002) 236-248
15. Sengupta D., Leontiadou H., Mark A.E., and Marrink S.-J. Toroidal pores formed by antimicrobial peptides show significant disorder. Biochim. Biophys. Acta 1778 (2008) 2308-2317
16. Matsuzaki K., Sugishita K., Ishibe N., Ueha M., Nakata S., Miyajima K., and Epand R.M. Relationship of membrane curvature to the formation of pores by magainin 2. Biochemistry 37 (1998) 11856-11863
17. Tripathi A., and Gupta C.M. Transbilayer translocation of membrane phosphatidylserine and its role in macrophage invasion in Leishmania promastigotes. Mol. Biochem. Parasitol. 128 (2003) 1-9
18. Wanderley J.L., Moreira M.E., Benjamin A., Bonomo A.C., and Barcinski M.A. Mimicry of apoptotic cells by exposing phosphatidylserine participates in the establishment of amastigotes of Leishmania (L) amazonensis in mammalian hosts. J. Immunol. 176 (2006) 1834-1839
19. Kobayashi S., Chikushi A., Tougu S., Imura Y., Nishida M., Yano Y., and Matsuzaki K. Membrane translocation mechanism of the antimicrobial peptide buforin 2. Biochemistry 43 (2004) 15610-15616
20. Mattila J.P., Sabatini K., and Kinnunen P.K. Oxidized phospholipids as potential molecular targets for antimicrobial peptides. Biochim. Biophys. Acta 1778 (2008) 2041-2050
21. Gantt K.R., Goldman T.L., McCormick M.L., Miller M.A., Jeronimo S.M., Nascimento E.T., Britigan B.E., and Wilson M.E. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J. Immunol. 167 (2001) 893-901
22. Turrens J.F. Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. Mol. Aspects Med. 25 (2004) 211-220
23. Radfar A., Diez A., and Bautista J.M. Chloroquine mediates specific proteome oxidative damage across the erythrocytic cycle of resistant Plasmodium falciparum. Free Radic. Biol. Med. 44 (2008) 2034-2042
24. Mason A.J., Marquette A., and Bechinger B. Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys. J. 93 (2007) 4289-4299
25. Wieprecht T., Beyermann M., and Seelig J. Binding of antibacterial magainin peptides to electrically neutral membranes: thermodynamics and structure. Biochemistry 38 (1999) 10377-10387
26. Sood R., and Kinnunen P.K. Cholesterol, lanosterol, and ergosterol attenuate the membrane association of LL-37 (W27F) and temporin L. Biochim. Biophys. Acta. 1778 (2008) 1460-1466
27. Zhao H., and Kinnunen P.K. Binding of the antimicrobial peptide temporin L to liposomes assessed by Trp fluorescence. J. Biol. Chem. 277 (2002) 25170-25177
28. Zhao H., Rinaldi A.C., Di Giulio A., Simmaco M., and Kinnunen P.K. Interactions of the antimicrobial peptides temporins with model biomembranes. Comparison of temporins B and L. Biochemistry 41 (2002) 4425-4436
29. Wojcik C., Sawicki W., Marianowski P., Benchaib M., Czyba J.C., and Guerin J.F. Cyclodextrin enhances spermicidal effects of magainin-2-amide. Contraception 62 (2000) 99-103
30. Roberts C.W., McLeod R., Rice D.W., Ginger M., Chance M.L., and Goad L.J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126 (2003) 129-142
31. Gallucci E., Meleleo D., Micelli S., and Picciarelli V. Magainin 2 channel formation in planar lipid membranes: the role of lipid polar groups and ergosterol. Eur. Biophys. J. 32 (2003) 22-32
32. De Lucca A.J., Bland J.M., Jacks T.J., Grimm C., and Walsh T.J. Fungicidal and binding properties of the natural peptides cecropin B and dermaseptin. Med. Mycol. 36 (1998) 291-298
33. Robertson L.J., and Gjerde B.K. Cryptosporidium oocysts: challenging adversaries?. Trends Parasitol. 23 (2007) 344-347
34. Giacometti A., Cirioni O., Del Prete M.S., Barchiesi F., and Scalise G. Short-term exposure to membrane-active antibiotics inhibits Cryptosporidium parvum infection in cell culture. Antimicrob. Agents Chemother. 44 (2000) 3473-3475
35. Giacometti A., Cirioni O., Del Prete M.S., Skerlavaj B., Circo R., Zanetti M., and Scalise G. In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. J. Antimicrob. Chemother. 51 (2003) 843-847
36. Templeton T.J., Lancto C.A., Vigdorovich V., Liu C., London N.R., Hadsall K.Z., and Abrahamsen M.S. The Cryptosporidium oocyst wall protein is a member of a multigene family and has a homolog in Toxoplasma. Infect. Immun. 72 (2004) 980-987
37. Gull K. Host-parasite interactions and trypanosome morphogenesis: a flagellar pocketful of goodies. Curr. Opin. Microbiol. 6 (2003) 365-370
38. Homans S.W., Mehlert A., and Turco S.J. Solution structure of the lipophosphoglycan of Leishmania donovani. Biochemistry 31 (1992) 654-661
39. Guerrero E., Saugar J.M., Matsuzaki K., and Rivas L. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob. Agents Chemother. 48 (2004) 2980-2986
40. Mangoni M.L. Temporins, anti-infective peptides with expanding properties. Cell. Mol. Life Sci. 63 (2006) 1060-1069
41. Mangoni M.L., Papo N., Saugar J.M., Barra D., Shai Y., Simmaco M., and Rivas L. Effect of natural l- to d-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry 45 (2006) 4266-4276
42. Yao C., Donelson J.E., and Wilson M.E. The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol. Biochem. Parasitol. 132 (2003) 1-16
43. Kulkarni M.M., McMaster W.R., Kamysz E., Kamysz W., Engman D.M., and McGwire B.S. The major surface-metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptide-induced apoptotic killing. Mol. Microbiol. 62 (2006) 1484-1497
44. Mangoni M.L., Saugar J.M., Dellisanti M., Barra D., Simmaco M., and Rivas L. Temporins, small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. 280 (2005) 984-990
45. Bahr V., Stierhof Y.D., Ilg T., Demar M., Quinten M., and Overath P. Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana. Mol. Biochem. Parasitol. 58 (1993) 107-121
46. Krugliak M., Feder R., Zolotarev V.Y., Gaidukov L., Dagan A., Ginsburg H., and Mor A. Antimalarial activities of dermaseptin S4 derivatives. Antimicrob. Agents Chemother. 44 (2000) 2442-2451
47. Ghosh J.K., Shaool D., Guillaud P., Ciceron L., Mazier D., Kustanovich I., Shai Y., and Mor A. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. J. Biol. Chem. 272 (1997) 31609-31616
48. Dagan A., Efron L., Gaidukov L., Mor A., and Ginsburg H. In vitro antiplasmodium effects of dermaseptin S4 derivatives. Antimicrob. Agents Chemother. 46 (2002) 1059-1066
49. Efron L., Dagan A., Gaidukov L., Ginsburg H., and Mor A. Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture. J. Biol. Chem. 277 (2002) 24067-24072
50. Lanzer M., Wickert H., Krohne G., Vincensini L., and Braun Breton C. Maurer's clefts: a novel multi-functional organelle in the cytoplasm of Plasmodium falciparum-infected erythrocytes. Int. J. Parasitol. 36 (2006) 23-36
51. Haldar K., Mohandas N., Bhattacharjee S., Harrison T., Hiller N.L., Murphy S., Tamez P., and van Ooij C. Trafficking and the tubovesicular membrane network. In: Sherman I.W. (Ed) (2005), Molecular approaches to malaria ASM Press, Washington, D.C. 253-271
52. Ginsburg H., and Stein W.D. How many functional transport pathways does Plasmodium falciparum induce in the membrane of its host erythrocyte?. Trends Parasitol. 21 (2005) 118-121
53. Vial H.J., and Ben Mamoun C. Plasmodium lipids: metabolism and function. In: Sherman I.W. (Ed) (2005), Molecular approaches to malaria ASM Press, Washington, D.C. 327-352
54. Schwartz R.S., Olson J.A., Raventos-Suarez C., Yee M., Heath R.H., Lubin B., and Nagel R.L. Altered plasma membrane phospholipid organization in Plasmodium falciparum-infected human erythrocytes. Blood 69 (1987) 401-407
55. Maguire P.A., and Sherman I.W. Phospholipid composition, cholesterol content and cholesterol exchange in Plasmodium falciparum-infected red cells. Mol. Biochem. Parasitol. 38 (1990) 105-112
56. Jackson K.E., Spielmann T., Hanssen E., Adisa A., Separovic F., Dixon M.W., Trenholme K.R., Hawthorne P.L., Gardiner D.L., Gilberger T., and Tilley L. Selective permeabilization of the host cell membrane of Plasmodium falciparum-infected red blood cells with streptolysin O and equinatoxin II. Biochem. J. 403 (2007) 167-175
57. Sherman I.W., and Greenan J.R. Altered red cell membrane fluidity during schizogonic development of malarial parasites (Plasmodium falciparum and P. lophurae). Trans. R. Soc. Trop. Med. Hyg. 78 (1984) 641-644
58. Gelhaus C., Jacobs T., Andra J., and Leippe M. The antimicrobial peptide NK-2, the core region of mammalian NK-lysin, kills intraerythrocytic Plasmodium falciparum. Antimicrob. Agents Chemother. 52 (2008) 1713-1720
59. Giacometti A., Cirioni O., Barchiesi F., Del Prete M.S., and Scalise G. Antimicrobial activity of polycationic peptides. Peptides 20 (1999) 1265-1273
60. Giacometti A., Cirioni O., Del Prete M.S., Barchiesi F., Fineo A., and Scalise G. Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. J. Antimicrob. Chemother. 47 (2001) 97-99
61. Giacometti A., Cirioni O., Barchiesi F., Fortuna M., and Scalise G. In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 18 (1999) 827-829
62. Giacometti A., Cirioni O., Barchiesi F., Ancarani F., and Scalise G. In vitro anti-cryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. J. Antimicrob. Chemother. 45 (2000) 651-654
63. Giacometti A., Cirioni O., Barchiesi F., Caselli F., and Scalise G. In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. J. Antimicrob. Chemother. 44 (1999) 403-406
64. Giacometti A., Cirioni O., Barchiesi F., and Scalise G. Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. J. Antimicrob. Chemother. 45 (2000) 375-377
65. Valigurova A., Jirku M., Koudela B., Gelnar M., Modry D., and Slapeta J. Cryptosporidia: epicellular parasites embraced by the host cell membrane. Int. J. Parasitol. 38 (2008) 913-922
66. Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell. Microbiol. 10 (2008) 1221-1234
67. Gregory D.J., Sladek R., Olivier M., and Matlashewski G. Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect. Immun. 76 (2008) 1186-1192
68. Rodriguez N.E., Chang H.K., and Wilson M.E. Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect. Immun. 72 (2004) 2111-2122
69. Chakraborty D., Banerjee S., Sen A., Banerjee K.K., Das P., and Roy S. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J. Immunol. 175 (2005) 3214-3224
70. Chen Q., Wade D., Kurosaka K., Wang Z.Y., Oppenheim J.J., and Yang D. Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. J. Immunol. 173 (2004) 2652-2659
71. Auvynet C., El Amri C., Lacombe C., Bruston F., Bourdais J., Nicolas P., and Rosenstein Y. Structural requirements for antimicrobial versus chemoattractant activities for dermaseptin S9. FEBS J. 275 (2008) 4134-4151
72. Ammar B., Perianin A., Mor A., Sarfati G., Tissot M., Nicolas P., Giroud J.P., and Roch-Arveiller M. Dermaseptin, a peptide antibiotic, stimulates microbicidal activities of polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 247 (1998) 870-875
73. Rosenfeld Y., Barra D., Simmaco M., Shai Y., and Mangoni M.L. A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer. J. Biol. Chem. 281 (2006) 28565-28574
74. Hara T., Mitani Y., Tanaka K., Uematsu N., Takakura A., Tachi T., Kodama H., Kondo M., Mori H., Otaka A., Nobutaka F., and Matsuzaki K. Heterodimer formation between the antimicrobial peptides magainin 2 and PGLa in lipid bilayers: a cross-linking study. Biochemistry 40 (2001) 12395-12399
75. Schuster F.L., and Jacob L.S. Effects of magainins on ameba and cyst stages of Acanthamoeba polyphaga. Antimicrob. Agents Chemother. 36 (1992) 1263-1271
76. Maloy W.L., and Kari U.P. Structure-activity studies on magainins and other host defense peptides. Biopolymers 37 (1995) 105-122
77. Hancock R.E.W., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006) 1551-1557
78. Tossi A. Host defense peptides: roles and applications. Curr. Protein Pept. Sci 6 (2005) 1-3
79. Kustanovich I., Shalev D.E., Mikhlin M., Gaidukov L., and Mor A. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J. Biol. Chem. 277 (2002) 16941-16951
80. Matsuzaki K., Nakamura A., Murase O., Sugishita K., Fujii N., and Miyajima K. Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry 36 (1997) 2104-2111
81. Dathe M., Nikolenko H., Meyer J., Beyermann M., and Bienert M. Optimization of the antimicrobial activity of magainin peptides by modification of charge. FEBS Lett. 501 (2001) 146-150
82. Huang C.M., Chen H.C., and Zierdt C.H. Magainin analogs effective against pathogenic protozoa. Antimicrob. Agents Chemother. 34 (1990) 1824-1826
83. Shalev D.E., Rotem S., Fish A., and Mor A. Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13). J. Biol. Chem. 281 (2006) 9432-9438
84. Sal-Man N., Oren Z., and Shai Y. Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry 41 (2002) 11921-11930
85. Grell D., Richardson J.S., and Mutter M. Protein design and folding: template trapping of self-assembled helical bundles. J. Pept. Sci. 7 (2001) 146-151
86. Feder R., Nehushtai R., and Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides 22 (2001) 1683-1690
87. Shalev D.E., Mor A., and Kustanovich I. Structural consequences of carboxyamidation of dermaseptin S3. Biochemistry 41 (2002) 7312-7317
88. Mor A., Hani K., and Nicolas P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J. Biol. Chem. 269 (1994) 31635-31641
89. Mignogna G., Simmaco M., and Barra D. Occurrence and function of d-amino acid-containing peptides and proteins: antimicrobial peptides. EXS 85 (1998) 29-36
90. Mignogna G., Simmaco M., Kreil G., and Barra D. Antibacterial and haemolytic peptides containing d-alloisoleucine from the skin of Bombina variegata. EMBO J. 12 (1993) 4829-4832
91. M. Simmaco, G. Kreil, D. Barra, Bombinins, antimicrobial peptides from Bombina species, Biochim. Biophys. Acta in press.
92. Chicharro C., Granata C., Lozano R., Andreu D., and Rivas L. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob. Agents Chemother. 45 (2001) 2441-2449
93. Avrahami D., and Shai Y. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry 41 (2002) 2254-2263
94. Radzishevsky I.S., Rotem S., Zaknoon F., Gaidukov L., Dagan A., and Mor A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 49 (2005) 2412-2420
95. Davies A.J., and Johnston M.R. The biology of some intraerythrocytic parasites of fishes, amphibia and reptiles. Adv. Parasitol. 45 (2000) 1-107
96. Desser S.S. The blood parasites of anurans from Costa Rica with reflections on the taxonomy of their trypanosomes. J. Parasitol. 87 (2001) 152-160
97. Yoshikawa H., Morimoto K., Nagashima M., and Miyamoto N. A survey of Blastocystis infection in anuran and urodele amphibians. Vet. Parasitol. 122 (2004) 91-102
98. Densmore C.L., and Green D.E. Diseases of amphibians. Ilar J. 48 (2007) 235-254
99. Mangoni M.L., Miele R., Renda T.G., Barra D., and Simmaco M. The synthesis of antimicrobial peptides in the skin of Rana esculenta is stimulated by microorganisms. FASEB J. 15 (2001) 1431-1432
100. Rollins-Smith L.A., Woodhams D.C., Reinert L.K., Vredenburg V.T., Briggs C.J., Nielsen P.F., and Conlon J.M. Antimicrobial peptide defenses of the mountain yellow-legged frog (Rana muscosa). Dev. Comp. Immunol. 30 (2006) 831-842
101. Nicolas P., Vanhoye D., and Amiche M. Molecular strategies in biological evolution of antimicrobial peptides. Peptides 24 (2003) 1669-1680
102. Ali M.F., Lips K.R., Knoop F.C., Fritzsch B., Miller C., and Conlon J.M. Antimicrobial peptides and protease inhibitors in the skin secretions of the crawfish frog, Rana areolata. Biochim. Biophys. Acta 1601 (2002) 55-63
103. Thompson A.H., Bjourson A.J., Orr D.F., Shaw C., and McClean S. A combined mass spectrometric and cDNA sequencing approach to the isolation and characterization of novel antimicrobial peptides from the skin secretions of Phyllomedusa hypochondrialis azurea. Peptides 28 (2007) 1331-1343
104. Li J., Xu X., Xu C., Zhou W., Zhang K., Yu H., Zhang Y., Zheng Y., Rees H.H., Lai R., Yang D., and Wu J. Anti-infection peptidomics of amphibian skin. Mol. Cell. Proteomics 6 (2007) 882-894
105. Thompson A.H., Bjourson A.J., Orr D.F., Shaw C., and McClean S. Amphibian skin secretomics: application of parallel quadrupole time-of-flight mass spectrometry and peptide precursor cDNA cloning to rapidly characterize the skin secretory peptidome of Phyllomedusa hypochondrialis azurea: discovery of a novel peptide family, the hyposins. J. Proteome. Res. 6 (2007) 3604-3613
106. Shi J., and Camus A.C. Hepcidins in amphibians and fishes: antimicrobial peptides or iron-regulatory hormones?. Dev. Comp. Immunol. 30 (2006) 746-755
107. Moore K.S., Bevins C.L., Brasseur M.M., Tomassini N., Turner K., Eck H., and Zasloff M. Antimicrobial peptides in the stomach of Xenopus laevis. J. Biol. Chem. 266 (1991) 19851-19857
108. Park C.B., Kim H.S., and Kim S.C. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244 (1998) 253-257
109. Lee H.S., Park C.B., Kim J.M., Jang S.A., Park I.Y., Kim M.S., Cho J.H., and Kim S.C. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 271 (2008) 47-55
110. Ghavami S., Asoodeh A., Klonisch T., Halayko A.J., Kadkhoda K., Kroczak T.J., Gibson S.B., Booy E.P., Naderi-Manesh H., and Los M. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J. Cell. Mol. Med. 12 (2008) 1005-1022
111. Morton C.O., Dos Santos S.C., and Coote P. An amphibian-derived, cationic, alpha-helical antimicrobial peptide kills yeast by caspase-independent but AIF-dependent programmed cell death. Mol. Microbiol. 65 (2007) 494-507
112. Morton C.O., Hayes A., Wilson M., Rash B.M., Oliver S.G., and Coote P. Global phenotype screening and transcript analysis outlines the inhibitory mode(s) of action of two amphibian-derived, alpha-helical, cationic peptides on Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 51 (2007) 3948-3959
113. Conlon J.M., Al-Ghaferi N., Abraham B., and Leprince J. Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents. Methods 42 (2007) 349-357
114. Conlon J.M., Al-Kharrge R., Ahmed E., Raza H., Galadari S., and Condamine E. Effect of aminoisobutyric acid (Aib) substitutions on the antimicrobial and cytolytic activities of the frog skin peptide, temporin-1DRa. Peptides 28 (2007) 2075-2080
115. Unger T., Oren Z., and Shai Y. The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action. Biochemistry 40 (2001) 6388-6397
116. Mantyla T., Sirola H., Kansanen E., Korjamo T., Lankinen H., Lappalainen K., Valimaa A.L., Harvima I., and Narvanen A. Effect of temporin A modifications on its cytotoxicity and antimicrobial activity. APMIS 113 (2005) 497-505
117. Park C.B., Yi K.S., Matsuzaki K., Kim M.S., and Kim S.C. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8245-8250
118. Lee D.G., Park Y., Kim P.I., Jeong H.G., Woo E.R., and Hahm K.S. Influence on the plasma membrane of Candida albicans by HP (2-9)-magainin 2 (1-12) hybrid peptide. Biochem. Biophys. Res. Commun. 297 (2002) 885-889
119. Wade D., Flock J.I., Edlund C., Lofving-Arvholm I., Sallberg M., Bergman T., Silveira A., Unson C., Rollins-Smith L., Silberring J., Richardson M., Kuusela P., and Lankinen H. Antibiotic properties of novel synthetic temporin A analogs and a cecropin A-temporin A hybrid peptide. Protein Pept. Lett. 9 (2002) 533-543
120. Kamysz W., Mickiewicz B., Greber K., and Rodziewicz-Motowidlo S. Conformational solution studies of the anti-microbial temporin A retro-analogues by using NMR spectroscopy. J. Pept. Sci. 13 (2007) 327-333
121. Luque-Ortega J.R., Saugar J.M., Chiva C., Andreu D., and Rivas L. Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP. Biochem. J. 375 (2003) 221-230
122. Ingham A.B., and Moore R.J. Recombinant production of antimicrobial peptides in heterologous microbial systems. Biotechnol. Appl. Biochem. 47 (2007) 1-9
123. Sonda S., and Hehl A.B. Lipid biology of Apicomplexa: perspectives for new drug targets, particularly for Toxoplasma gondii. Trends Parasitol. 22 (2006) 41-47
124. Pomorski T., Holthuis J.C., Herrmann A., and van Meer G. Tracking down lipid flippases and their biological functions. J. Cell. Sci. 117 (2004) 805-813
125. Docampo R. Recent developments in the chemotherapy of Chagas disease. Curr. Pharm. Des. 7 (2001) 1157-1164
126. Urbina J.A., Marchan E., Lazardi K., Visbal G., Apitz-Castro R., Gil F., Aguirre T., Piras M.M., and Piras R. Inhibition of phosphatidylcholine biosynthesis and cell proliferation in Trypanosoma cruzi by ajoene, an antiplatelet compound isolated from garlic. Biochem. Pharmacol. 45 (1993) 2381-2387
127. Contreras L.M., Vivas J., and Urbina J.A. Altered lipid composition and enzyme activities of plasma membranes from Trypanosoma (Schizotrypanum) cruzi epimastigotes grown in the presence of sterol biosynthesis inhibitors. Biochem. Pharmacol. 53 (1997) 697-704
128. Urbina J.A., Lira R., Visbal G., and Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44 (2000) 2498-2502
129. Lira R., Contreras L.M., Rita R.M., and Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47 (2001) 537-546
130. Rakotomanga M., Blanc S., Gaudin K., Chaminade P., and Loiseau P.M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 51 (2007) 1425-1430
131. Liendo A., Visbal G., Piras M.M., Piras R., and Urbina J.A. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol. 104 (1999) 81-91
132. Hart D.T., Lauwers W.J., Willemsens G., Vanden Bossche H., and Opperdoes F.R. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol. Biochem. Parasitol. 33 (1989) 123-134
133. Rakotomanga M., Saint-Pierre-Chazalet M., and Loiseau P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 49 (2005) 2677-2686
134. Rodrigues J.C., Attias M., Rodriguez C., Urbina J.A., and Souza W. Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob. Agents Chemother. 46 (2002) 487-499
135. Roggero R., Zufferey R., Minca M., Richier E., Calas M., Vial H., and Ben Mamoun C. Unraveling the mode of action of the antimalarial choline analog G25 in Plasmodium falciparum and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48 (2004) 2816-2824
136. Gwadz R.W., Kaslow D., Lee J.Y., Maloy W.L., Zasloff M., and Miller L.H. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect. Immun. 57 (1989) 2628-2633
137. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol .Rev. 19 (2006) 111-126
138. Boman H.G., Wade D., Boman I.A., Wahlin B., and Merrifield R.B. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett. 259 (1989) 103-106
139. Soravia E., Martini G., and Zasloff M. Antimicrobial properties of peptides from Xenopus granular gland secretions. FEBS Lett. 228 (1988) 337-340
140. Zasloff M., Martin B., and Chen H.C. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 910-913
141. Gaidukov L., Fish A., and Mor A. Analysis of membrane-binding properties of dermaseptin analogues: relationships between binding and cytotoxicity. Biochemistry 42 (2003) 12866-12874
142. 2-terminal α-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity. J. Biol. Chem. 269 (1994) 1934-1939
143. Brand G.D., Leite J.R., Silva L.P., Albuquerque S., Prates M.V., Azevedo R.B., Carregaro V., Silva J.S., Sa V.C., Brandao R.A., and Bloch Jr. C. Dermaseptins from Phyllomedusa oreades and Phyllomedusa distincta. Anti-Trypanosoma cruzi activity without cytotoxicity to mammalian cells. J. Biol. Chem. 277 (2002) 49332-49340
144. Hernandez C., Mor A., Dagger F., Nicolas P., Hernandez A., Benedetti E.L., and Dunia I. Functional and structural damage in Leishmania mexicana exposed to the cationic peptide dermaseptin. Eur. J. Cell. Biol. 59 (1992) 414-424
145. Brand G.D., Leite J.R., de Sa Mandel S.M., Mesquita D.A., Silva L.P., Prates M.V., Barbosa E.A., Vinecky F., Martins G.R., Galasso J.H., Kuckelhaus S.A., Sampaio R.N., Furtado Jr. J.R., Andrade A.C., and Bloch Jr. C. Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia). Biochem. Biophys. Res. Commun. 347 (2006) 739-746
146. Abbassi F., Oury B., Blasco T., Sereno D., Bolbach G., Nicolas P., Hani K., Amiche M., and Ladram A. Isolation, characterization and molecular cloning of new temporins from the skin of the North African ranid Pelophylax saharica. Peptides 29 (2008) 1526-1533
147. Leite J.R., Silva L.P., Rodrigues M.I., Prates M.V., Brand G.D., Lacava B.M., Azevedo R.B., Bocca A.L., Albuquerque S., and Bloch Jr. C. Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus. Peptides 26 (2005) 565-573
148. Vouldoukis I., Shai Y., Nicolas P., and Mor A. Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett. 380 (1996) 237-240
149. Conlon J.M. Reflections on a systematic nomenclature for antimicrobial peptides from the skins of frogs of the family Ranidae. Peptides 29 (2008) 1815-1819
150. M. Amiche, A. Ladram, P. Nicolas, A consistent nomenclature of antimicrobial peptides isolated from frogs of the subfamily Phyllomedusinae, Peptides (in press).
151. Lofgren S.E., Miletti L.C., Steindel M., Bachere E., and Barracco M.A. Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp. Parasitol. 118 (2008) 197-202
152. Savoia D., Guerrini R., Marzola E., and Salvadori S. Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorg. Med. Chem. 16 (2008) 8205-8209